Peña LSP, Barbosa CLM, Guerrero DAS, Colunga PPR

Language: Spanish
References: 12
Page: 46-51
PDF size: 288.50 Kb.

ABSTRACT

Objective: To analyze the incidence of ocular graft versus host disease in our center, its treatment and characteristics, besides the effect of the disease on survival of patients.
Materials and Methods: An observational, retrospective study was carried out in patients older than 17 years with a hematological diagnosis in whom an allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed at the Hospital Universitario Dr. José E González, Nuevo Leon, Mexico, from January 2015 to December 2021.
Results: A total of 204 patients underwent allo-HSCT of which 83 patients developed graft versus host disease (GVHD) at some point and 22 (26.6%) of these developed ocular graft versus host disease (oGVHD). We observed 9/22 patients with mild oGvHD, 11/22 with moderate and 2/22 with severe. Out of 22 patients, 10 received systemic steroid, 6 ophthalmic cyclosporine and 6 rituximab. Overall survival was 63% at 33-month follow-up. The clinical manifestations were dry eye, conjunctivitis, a combination of these and corneal involvement. There was no significant difference (p = 0.169) in overall survival or in ocular graft progression between patients who were assessed by ophthalmology versus those who were not.
Conclusions: We found no relationship between survival and graft progression of patients who presented with ocular graft versus host disease with follow-up only by a hematologist or by an ophthalmologist.

REFERENCES

1. Kim H. Treatments for children and adolescents with AML.Blood Res 2020; 55 (S1): S5-S13. doi: 10.5045/br.2020.S002.

2. Chakraverty R, Teshima T. Graft-versus-host disease: adisorder of tissue regeneration and repair. Blood 2021;138 (18): 1657-1665. doi: 10.1182/blood.2021011867.

3. Welniak LA, Blazar BR, Murphy WJ. Immunobiology ofallogeneic hematopoietic stem cell transplantation. AnnuRev Immunol 2007; 25: 139-70. doi: 10.1146/annurev.immunol.25.022106.141606.

4. Lee SJ. Classification systems for chronic graft-versushostdisease. Blood 2017; 129 (1): 30-37. doi: 10.1182/blood-2016-07-686642. Flowers ME, Inamoto Y, CarpenterPA, et al. Comparative analysis of risk factors for acutegraft-versus-host disease and for chronic graft-versus-hostdisease according to National Institutes of Health consensuscriteria. Blood 2011; 117: 3214-3219.

5. Westeneng AC, Hettinga Y, Lokhorst H, Verdonock L, et al.Ocular graft-versus-host disease after allogeneic stem celltransplantation. Cornea 2010; 29 (7): 758-63. doi: 10.1097/ICO.0b013e3181ca321c.

6. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease:a review. Surv Ophthalmol 2013; 58 (3): 233-51. doi:10.1016/j.survophthal.2012.08.004.

7. Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al.Diagnosis and treatment of ocular chronic graft-versushostdisease: report from the German-Austrian-SwissConsensus Conference on Clinical Practice in chronicGVHD. Cornea 2012; 31 (3): 299-310. doi: 10.1097/ICO.0b013e318226bf97.

8. Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National Institutesof Health Consensus Development Project on Criteria forClinical Trials in Chronic Graft-versus-Host Disease: prefaceto the series. Biol Blood Marrow Transplant 2015; 21 (3):387-8. doi: 10.1016/j.bbmt.2014.12.035.

9. Nair S, Vanathi M, Mukhija R, Tandon R, Jain S, OgawaY. Update on ocular graft-versus-host disease. Indian JOphthalmol 2021; 69 (5): 1038-1050.

10. Peña-Lozano SP, Barbosa-Castillo LM, Partida-García AE, etal. Ocular graft-versus-host-disease: an update of immunepathogenesis and therapies. Medicina Universitaria 2022;24 (3): 124-128.

11. Cantú-Rodríguez OG, Vázquez-Mellado A, González-TreviñoJL, et al. Cyclosporine A for the prevention of ocular graftversus host disease in allogeneic hematopoietic stem celltransplant recipients is safe and feasible. Acta Haematol2020; 143 (5): 425-431.

12. Kim SK, Couriel D, Ghosh S, Champlin R. Ocular graft vs.Host disease experience from MD Anderson cancer center:newly described clinical spectrum and new approachto the management of stage III and IV ocular GVHD. BiolBlood Marrow Transplant 2006; 12: 49-50. https://doi.org/10.1016/j.bbmt.2005.11.155.